Nature’s Derivative(s) as Alternative Anti-Alzheimer’s Disease Treatments

Anuja Sharma and Yatender Kumar*
Department of Biological Sciences and Engineering (BSE), Netaji Subhas University of Technology (NSUT), Formerly Netaji Subhas Institute of Technology (NSIT), Azad Hind Fauz Marg, New Delhi, India

Accepted 16 September 2019

Abstract. Alzheimer’s disease (AD), the ‘Plague of Twenty-First Century,’ is a crippling neurodegenerative disease that affects a majority of the older population globally. By 2050, the incidence of AD is expected to rise to 135 million, while no treatment(s) that can reverse or control the progression of AD are currently available. The treatment(s) in use are limited in their ability to manage the symptoms or slow the progression of the disease and can lead to some severe side effects. The overall care is economically burdensome for the affected individuals as well as the caretakers or family members. Thus, there is a pressing need to identify and develop much safer alternative therapies that can better manage AD. This review discusses a multitude of such treatments borrowed from Ayurveda, traditional Chinese practices, meditation, and exercising for AD treatment. These therapies are in practice since ancient times and reported to be beneficial as anti-AD therapies. Ayurvedic drugs like turmeric, Brahmi, Ashwagandha, etc., management of stress by meditation, regular exercising, and acupuncture have been reported to be efficient in their anti-AD usage. Besides, a combination of vitamins and natural dietary intakes is likely to play a significant role in combating AD. We conclude that the use of such alternative strategies will be a stepping-stone in preventing, treating, curing, or managing the disease.

Keywords: Acupuncture, alternative treatments, Alzheimer’s disease, Ayurveda, exercise, meditation

INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disease that was first described by German psychiatrist and neuropathologist, Alois Alzheimer in 1906 [1]. It results in deterioration of cognition and memory, ultimately leading to the loss of a person’s ability to carry out day to day activities independently. It is the most common form of dementia, contributing to 60–70% of the cases [2]. Generally observed in people around 65 years of age or more, the onset of the disease is associated with aging and occasionally found in younger people [3]. Currently, no cure is available for AD, which is often referred to as the ‘Plague of Twenty-First Century’ due to the estimated sweeping escalation in the number of its cases from 48 million to 135 million by 2050 [4]. It calls for finding a cure or efficient methods of preventing the disease condition to manage and minimize its proliferation effectively.

What happens in AD?

Neuronal damage and death are widespread in the case of AD as critical processes like metabolism, communication among the neurons and with other brain cells, repair, remodeling, and regeneration gets disrupted. Generally, the disease progresses with the
onset of aging. In the initial stages, neurons of the entorhinal cortex and hippocampus, responsible for memory, are destroyed. The disease then proceeds to the later stage to affect areas accountable for reasoning, language, and social behavior of the cerebral cortex. This fatal neurodegenerative disease then affects other areas of the brain, ultimately leading to the stage where the patient becomes incapable of functioning and living independently, before death.

The significant changes taking place in the brain at the molecular level are:

1. **Oxidative stress.** Reactive oxygen species (ROS) bring about the oxidative stress, especially in the case of age-related disorders like AD. Oxidative damage occurs early in the AD patient’s brain. Its impact can be seen even before the plaque pathology is initiated as it precedes amyloid-β (Aβ) deposition as well as abnormal formation of intracellular neurofibrillary tau protein tangles. ROS also lead to neurodegenerative processes and neuronal death, at the cellular and tissue levels [5].

2. **Formation of Aβ plaques.** Formation of Aβ proteins occurs due to breakdown of the amyloid-β protein precursor (AβPP). These proteins begin to clump together to form plaques between neurons at abnormal levels. Ultimately, these clumps result in disruption of cellular function [6].

3. **Formation of neurofibrillary tangles.** Accumulation of abnormally high levels of hyperphosphorylated tau protein inside the neurons results in the generation of neurofibrillary tangles. Tau protein in healthy neurons is responsible for binding to and stabilizing microtubules [7]. However, after detaching from microtubules, tau sticks to other tau molecules in case of AD and forms threads that join together to form tangles that lead to blockage of synaptic communication between the neurons [8]. Due to the breakdown of a retrograde barrier at the axon initial segment, tau proteins present in the axonal region of neurons get missorted to the somatodendritic compartment [9].

4. **Chronic inflammation.** Microglial cells act as macrophages of the brain, clearing cell debris, including Aβ plaques, toxins, and dead neurons. Astrocytes also help in removing the plaques and cell debris from the brain. In the case of AD, these microglial cells of the brain assem-

5. **Vascular attributions of AD.** AD may also cause Aβ accumulation in arteries of the brain, hardening of arteries, i.e., atherosclerosis, mini-strokes, etc. [11], and can reduce blood flow and oxygen supply to the brain. Ultimately, this leads to a degenerative and complicated cycle that is a cause as well as a consequence of AD [12].

6. **Brain atrophy.** Neuron cells are damaged and die in case of AD. Thus, the neural network may breakdown, and brain regions begin to shrink in volume [13].

The brain activity deterioration begins from the hippocampus in the medial temporal lobe, which is mainly related to memory and emotion. The deterioration then escalates, and the whole brain glucose metabolism is also affected, resulting in a reduction in neuronal processing of bilateral parietal and temporal lobes [14]. The parietal lobe is responsible for sensation, self-awareness, attention, memory retrieval, and theory of mind [15–17]. The temporal lobe is associated with episodic memory, emotions, and mood [18]. Thus, the regions affected by AD are responsible for the regulation of memory, emotions, and awareness.

**Current treatments for AD**

At present, there are a limited number of drugs available for the treatment of AD, and most of these can only treat the symptoms. These are inept at preventing the progression of the disease further or reversing its effects. The development of symptoms like memory loss is, however, slowed, prolonging life and alleviating the quality of life of the affected individuals. Some of the compounds used in case of mild to moderate AD are donepezil, rivastigmine, and galantamine. These are classified as cholinesterase inhibitors that prevent the breakdown of acetylcholine, necessary for memory and learning. For patients with moderate to severe AD, memantine, a N-methyl D-aspartate (NMDA) antagonist, is used [19]. A combination of memantine and donepezil is used for the same. Some other drugs are also used to treat depression, aggression, restlessness, and anxiety associated with AD. These include citalo-
pram, mirtazapine, sertraline, bupropion, duloxetine, and imipramine. However, the side effects of these drugs can be severe, often involving confusion, falls, dizziness, sleepiness, etc. and should be strictly taken as prescribed [20].

**Need for alternative treatments**

With the ever-increasing population and the growing life expectancy of individuals, AD incidences are also rising rapidly across the globe. As per the WHO factsheet on dementia, worldwide 50 million people are reported to have dementia, with 10 million new cases being added every year. It is also proposed that globally, one person develops dementia every 3 seconds [21]. This rapid increase necessitates the development of alternative treatment strategies to prevent and treat AD.

The currently available treatments have limited efficiency, a more significant number of side effects, and poor patient compliance. They are also burdensome for the patients and caregivers to bear as the socioeconomic costs of long-term attendance and hospital expenditure continue to rise annually [22]. This calls for the development of much safer alternative therapies that have been practiced since ancient times and have been reported to be beneficial in their use as anti-AD therapies. A multitude of such therapies can be borrowed from Ayurveda, traditional Chinese practices, meditation, and exercise. Many of the treatments aimed at fixing or preserving the functioning of synapses and cognition (the main attributes of AD) have proven to be useful for contributing in slowing the progression of AD and complementing the mainstream treatments currently in use.

Some of the alternative therapeutic and preventive strategies that can be adopted for long-term anti-AD beneficial effects are discussed in detail.

**AYURVEDA**

*Ayu* meaning longevity of life (*Chetananuvrutti*), *Ayurveda*, a Sanskrit word, is the ‘scripture of longevity’; it is the science of life and wellbeing that encourages a holistic view of treatment to maintain the equilibrium of the body, mind, and soul. This traditional system of medication is based on the five basic elements of the universe: space, fire, water, air, and earth [23]. It finds its roots in India and the Indian subcontinent, dating back to the Indus Valley Civilization (about 3,000 BC). Ayurveda not only cures but acts as an excellent preventive medication system that can delay the very onset of aging and ailments associated with it.

According to Ayurveda, disturbances in the *Tridosha* (Vata, Pitta, and Kapha) and *Triguna* (Sattva, Raja, and Tama) results in functional disorder of *Indriya* (cognitive and motor organs), *Mana* (psyche), and *Buddhi* (intellect). It leads to impaired memory or cognitive defects. Ayurvedic drugs help in maintaining and re-establishing the balance between *Tridosha* and *Triguna*. They also provide *Medhya* (intellect promoting) effect to improve the memory of the patients [24].

Recently, the world’s first Ayurvedic drug against cancer has been launched, which is non-chemical, non-synthetic, and has no side-effects. ‘Kudos CM9®’ (CSIR-IICB) was developed by the Ministry of Science & Technology, CSIR-IICB (Council of Scientific & Industrial Research-Indian Institute of Chemical Biology), India. It helps in cure as well as control the progression of benign and malignant tumors. It can also be used to prevent cancer in high-risk individuals. Ayurvedic herbal medications often have a biosafety profile and generally, do not show significant side-effects. Thus, there is a surge in research interest of Ayurvedic drugs. Mechanistic studies being carried out have helped in elucidating the effect and efficacy of these drugs on central nervous system (CNS) disorders, like AD.

Some Ayurvedic herbal/traditional plant-based drugs that can treat disorders of the nervous system and improve cognitive function and memory are discussed.

**Bacopa monniera (Brahmi)**

In the traditional Indian system of medicine, *Brahmi* acts as *Medhyarasayana* (from the Sanskrit words; ‘medhya,’ meaning intellect or cognition, and ‘rasayana,’ meaning ‘rejuvenation’) plant-derived nerve tonics that enhance memory, intellect, and aid mental health [25]. *Brahmi* extracts, functioning as a nootropic, are used for disorders like epilepsy, insomnia, anxiety, etc. [26] since they have effects that can enhance memory, help in anti-inflammation, and act as an analgesic, antipyretic, sedative, and antiepileptic agents [24]. Steroidal saponins, Bacosides A and B, are the active constituents of *Brahmi* that scavenge free radicals and inhibit lipoxygenase activity, reducing lipid peroxidation, thus protecting neurons of the hippocampus, prefrontal cortex, and striatum.
Also help in lowering the phospholipase A2 activity and comprise the first-line of treatment for AD and can act as a therapeutic agent in case of AD as in addition to reducing amyloid deposition; it can also prevent tau phosphorylation, both of these events being significant implications of the neurodegenerative disorder [49].

Curcuma longa (turmeric)

The yellow curry, Indian spice consists of a hydrophobic compound known as curcumin or diferuoylmethane ($C_{21}H_{20}O_6$). This polyphenolic yellow pigment has anti-inflammatory and antioxidant characteristics [47]. The molecule can cross the BBB and bind to Aβ, thus preventing its aggregation and fibril formation in vivo as well as in vitro [48]. Turmeric acts as a therapeutic agent in case of AD as in addition to reducing amyloid deposition; it can also prevent tau phosphorylation, both of these events being significant implications of the neurodegenerative disorder [49].

Curcumin shows anti-inflammatory characteristics by suppressing pro-inflammatory pathways by...
also inhibits phospholipase A2 and cyclooxygenase (COX-2) enzymes associated with the metabolism of neural membrane phospholipids to prostaglandins, thus reducing neuroinflammation [50]. It reduces oxidative damage and enhances cognitive function, especially in the case of aging by modulating the Nrf2-Keap1 (Kelch-like ECH-associated protein 1) pathway [47]. Nrf2 bound to Keap1 and present in the cytoplasm get released upon binding of curcumin to Keap1. It then translocates to the nucleus and binds to antioxidant responsive elements in DNA as a heterodimer, thus, targeting the genes controlling the expression of antioxidant enzymes, DNA repair enzymes, molecular chaperones, and anti-inflammatory response proteins. These proteins lead to the lowering of ROS production and aid the cell’s ability to fix any damage that follows [51].

A study also established that regular curry consumers performed better on the standard test (Mini-Mental State Examination, MMSE) of cognitive function than those who have never or rarely consumed it [52]. It also has the potential to lower cholesterol, inhibit acetylcholinesterase, mediate insulin signaling pathway, metal-chelation (binds copper) that prevents cerebral deregulation caused by bio-metal toxicity, and decrease microglia formation [53, 54]. It naturally has lower bioavailability, but when consumed with black pepper (Piper nigrum), its bioavailability and absorption rate increases due to the active ingredient 'piperine' of black pepper [55]. The lower rates of AD in the Indian population have also been attributed to the extensive consumption of turmeric, hinting at the neuroprotective role of turmeric [55]. The paste made from its small leaves along with its flowers and roots can be consumed regularly.

**Guggulu**

This pale yellow or brown oleo-gum resin is an exudate from cracks, fissures, or incisions on the bark of Commiphora wightii, Commiphora mukul, Commiphora abyssinica, Commiphora molmol, and Commiphora Burseraceae [61]. It is composed of phenols, ferulic acids, and other non-phenolic aromatic acids that have the potential to scavenge superoxide radicals, thus, making it significant in combating neurodegenerative diseases that have oxidative stress as a substantial implication [62].

High cholesterol is among one of the risk factors of AD. **Guggulu** is essential in modulating the activity of the cell membrane and regulating synaptic functions and neuronal plasticity. **Guggulu** helps in lowering cholesterol. Thus, this attribute of the drug contributes to reducing the frequency of AD development, since decreased neuronal cholesterol level leads to inhibition of Aβ-forming amyloidogenic pathway. It becomes possible due to the removal of precursor protein from cholesterol [63–65]. Studies have revealed that Z-guggulsterone pre-treatment of C57BL/6J mice models showing scopolamine (a muscarinic acetylcholine receptor antagonist)-induced memory impairments result in memory-improving effects due to the activation of the cAMP response element-binding protein (CREB)-brain-derived neurotrophic factor (BDNF)
signaling pathway [66]. Guggulipids also exhibit antioxidant effects, lower cholesterol, and show anti-acetylcholine esterase activities, thus improving the condition of streptozotocin-induced memory deficit mice model of dementia as demonstrated in a study by Saxena et al. It can lower serum LDL cholesterol as well as triglyceride levels [67]. Half-lives of Guggul and its derivatives in circulation in body and brain are yet to be elucidated.

**Ginkgo biloba (Ginkgo)**

Extracts of *Ginkgo* consist of flavonoid glycosides (containing quercetin, kaemferol, isorhamnetin, etc.), terpenoids (containing Ginkgolides A, B, C, and J and bilobalide), and organic acids [68]. The flavonoids and terpenoids are constituting the pharmacological components, while organic acids contribute to the water solubility of the extract [69]. It shows antioxidant activity attributed to its free radical scavenging action as shown in a study by Wei et al. in which pre-treatment of a cerebellar granule with *Ginkgo* reduced the oxidative damage caused by H$_2$O$_2$/FeSO$_4^+$ [70]. It also upregulates the protein level and activity of antioxidant enzymes like superoxide dismutase and catalase, to stabilize the cellular redox state, in addition to direct weakening of ROS [71, 72].

In LPS-activated microglial cells, *Ginkgo* extracts have been used to inhibit the release of prostaglandin E$_2$ (PGE$_2$), a pro-inflammatory mediator and pro-inflammatory cytokines, thus, displaying anti-inflammatory activity [73]. It also downregulates cytokines associated with inflammation, such as AGE- or LPS-induced nitric oxide (NO), TNFα, IL-6, and IL-1 [74]. The anti-inflammation effects may also be attributed to their platelet-activating factor (PAF)-antagonist activity. PAF is shown to have a role in regulating cytokines in inflammatory responses [68, 75].

*Ginkgo* also shows anti-apoptotic action and can act synergistically on multiple signaling apoptotic pathways, like maintaining the integrity of the mitochondrial membrane, blocking the apoptotic caspase cascade and apoptosome formation by preventing mitochondrial release of cytochrome c, enhancing the transcription of anti-apoptotic Bcl-2-like protein, attenuating the transcription of pro-apoptotic caspase-12, inactivating pro-apoptotic c-Jun N-terminal kinase (JNK), and inhibiting the cleavage of the vital effector protease caspase-3. Therefore, it blocks apoptosis and also prevents nuclear DNA fragmentation, the molecular hallmark of apoptosis [76, 77]. It also plays a protective role in preventing neurotoxicity caused by Aβ aggregation by blocking Aβ-induced events, such as ROS accumulation, glucose uptake, mitochondrial dysfunction, activation of Akt, JNK, and ERK 1/2 pathways, and apoptosis [67, 78, 79].

*Ginkgo* also shows other protective effects such as ion homeostasis, modulation of phosphorylation of tau protein, and induction of growth factor synthesis [80]. *Ginkgo* extracts can also upregulate expressions of nerve growth factor in mouse [81] and gliadervived neurotrophic factor and vascular endothelial growth factor in cultured rat cortical astrocytes [82]. In a study by Ihl et al., treatment of 404 patients having AD or vascular dementia with standardized extracts of *Ginkgo*, popularly known as Egb 761, resulted in a considerable enhancement in cognitive function and neuropsychiatric symptoms [83]. Of late a study by Savaskan et al., involving 1,628 patients with dementia, also showed the improvement of behavioral and psychological symptoms of dementia (except psychotic-like features) and caregiver distress caused by such symptoms by the administration of 22–24 weeks’ treatment with Egb 761 [84]. Recent studies have also shown the use of Egb761 in providing an appropriate environment to induce differentiation of stem cells into nerve cells, which opens new and fascinating avenues for stem cell treatment of neurodegenerative diseases [85]. *Ginkgo* extracts complexed with phosphatidylserine as a phytosome (Virtiva®) lead to an enhanced memory task performance due to increased bio-availability of active constituents of the extract when tested on 28 participants [86].

**Cinnamomum zeylanicum (Cinnamon)**

Cinnamon is composed of a flavonoid, cinnamaldehyde, that gives it the characteristic flavor and aroma. Most commonly present are *E*-cinnamaldehyde and *o*-methoxycinnamaldehyde [87]. Its extracts are shown to inhibit tau aggregation and filament formation. It is not detrimental to normal tau functioning. This inhibitory effect is due to the proanthocyanidin trimer molecule as well as cinnamaldehyde [88]. Cinnamaldehyde and an oxidized form of epicatechin (EC) (ECox) of the extracts can also dissolve tau tangles by binding to the two cysteine residues in tau. ECox can also prevent oxidation
of tau by ROS and H$_2$O$_2$, preventing tau tangles. EC also has the potential to sequester toxic and reactive by-products of oxidation, like acrolein [89]. It showed that a diet rich in proanthocyanidin, catechin, and epicatechin in monomeric, oligomeric, and polymeric forms could promote learning and memory in AD [90]. It can also inhibit the TLR4/NOX4 signaling, which can then lessen the oxidative stress/nitrative stress in case of neuronal damage and apoptosis pathways [91]. It also shows its neuroprotective effects by reducing the intracellular ROS production as well as expression of pro-inflammatory cytokines, IL-1β, IL-6, TNFα, and NF-kB to reduce inflammation, as shown in case of LPS-stimulated rats in a study by Zhao et al. [92] and can also increase synaptic plasticity [93]. Its polyphenolic compounds can counter Aβ aggregation; it also inhibits β-secretase and production of Aβ$_{40}$ in Chinese hamster ovary-APP CHO cells in vitro [94]. Thus, cinnamon extracts can target all three AD hallmarks: inhibition of acetylcholinesterase activity, Aβ formation/aggregation, and tau phosphorylation as summarized by S. Momtaz et al. [95].

**Panax ginseng (Ginseng)**

Ginsenosides, a type of terpenoid dammarane glycoside, constitute the major bioactive component of the plant extracts. Ginseng root has been observed to contain over and about 60 different ginsenosides, like Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1, Rg2, and Rg3 [96]. It shows anti-inflammatory effects due to inhibition of phosphorylation of p38MAPK and STAT1 in BV2 microglial cells, thus reducing LPS-induced mediators that are pro-inflammatory such as COX-2, TNFα, and inducible nitric oxide synthase (iNOS) [97].

Studies show the use of its extracts to improve thinking as well as working memory in case of AD patients [98]. Ginseng treatment improved Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog) and MMSE scores in AD patients [99].

A study also reported the potential of GP-17, a novel phytoestrogen isolated from ginseng, in the clearing of Aβ in vivo and in vitro in the AD mouse models, Swedish mutant of APP695 (APP695sw) and APP/PS1. The neuroprotective effect was due to the autophagy-based elimination of Aβ due to the activation of transcription factor EB responsible for lysosome biogenesis [100]. It is useful in the inhibition of formation of Aβ, stimulation of soluble AβPPα formation, anti-inflammation, anti-apoptosis, decreasing oxidation stress, and enhancing CNS cholinergic function to counter impairments and implications associated with AD [101,102]. Its combination with *Ginkgo* is expected to give better results [103].

**Cannabis sativa (cannabidiol)**

The main constituent of phytocannabinoids, cannabidiol (CBD), is present in *Cannabis sativa*. It is less toxic and lipophilic, making it easier to cross the BBB [104]. It can show anti-inflammation effects and inhibit the neuroinflammation caused by Aβ aggregation. CBD inhibits glial fibrillary acidic protein (GFAP) mRNA and protein expression, impairing iNOS and IL-1β protein expression, and their related release in Aβ-injected animals as shown by Esposito et al. [105].

CBD also prevents tau hyperphosphorylation in Aβ-stimulated PC12 neuronal cells due to reduction in phosphorylated glycogen synthase kinase 3β (p-GSK3β) which is the active form of GSK3β. GSK3β, called tau protein kinase, is associated with tau protein hyperphosphorylation, which then leads to the formation of tau tangles [106]. CBD treatment has shown to enhance memory and learning, along with decreasing IL-6 levels in AD mice models [107]. Chronic CBD treatment administered following the inception of AD-like symptoms, cognitive insufficiencies and formation of Aβ plaques, has shown to reverse social recognition memory and object recognition deficits in double transgenic APPswe/PS1E9 mice. The study also suggested the modulation of cytokine TNFα levels by CBD [108].

*Sativex*® is a combination of CBD and Δ$_9$-tetrahydrocannabinol (THC) in the ratio of 1 : 1. It has shown to reduce neuroinflammation and iNOS levels in the cerebral cortex and alleviate the stress-related behaviors in parkin-null, human tau overexpressing (PK−/−/TauVLW) mice. It also stimulated autophagy and reduced cortical and hippocampal Aβ, plaques, and phosphorylated tau [109]. THC/CBD treatment increased fear-associated learning and preserved object recognition memory. It also reduces cortical soluble Aβ$_{42}$ levels and changes plaque composition. Also, it effectively lowers inflammation and alters neuroinflammatory processes in APPxPS1 transgenic mice [110]. CBD shows anti-AD effects; antioxidant activity, anti-inflammation effects, and neuroprotective properties, and reduces Aβ generation and tau hyperphosphorylation in vitro [111].
| S.No. | Ayurveda drug | Active compounds | Major impacts |
|-------|---------------|------------------|---------------|
| 1.    | Brahmi        | Bacosides A and B | Nootropic effects |
|       |               |                  | Anti-inflammatory effects |
|       |               |                  | Scavenge free radicals |
|       |               |                  | Decrease Aβ deposition |
| 2.    | Mandukaparni  | Asiaticoside derivatives | Enhances memory retention |
|       |               |                  | Prevents cognitive impairments |
|       |               |                  | Anti-oxidant effects |
|       |               |                  | Lowers Aβ toxicity |
|       |               |                  | Alters mitochondrial dysfunction |
|       |               |                  | Alleviates mood |
| 3.    | Ashwagandha   | Withaferin A and Withanolide A | Enhances memory |
|       |               |                  | Anti-stress effects |
|       |               |                  | Immunomodulatory and anti-oxidant properties |
|       |               |                  | Prevents Aβ production |
|       |               |                  | Neurite outgrowth and neuroprotective effects |
|       |               |                  | Regenerates axons |
|       |               |                  | Reconstructs synapses |
| 4.    | Turmeric      | Curcumin or diferuloylmethane | Inhibits Aβ aggregation |
|       |               |                  | Anti-oxidant effects |
|       |               |                  | Anti-AChE effects |
|       |               |                  | Modifies insulin signaling pathways |
|       |               |                  | Lowers cholesterol |
|       |               |                  | Binds copper/metal-chelation |
|       |               |                  | Modulates microglia |
|       |               |                  | Prevents tau phosphorylation |
| 5.    | Shankhpushpi  | Glycosides, flavonoids, coumarins, anthocyanins, and alkaloids | Ameliorates memory and cognition |
|       |               |                  | Anti-oxidant effects |
|       |               |                  | Neutralizes tau induced neurotoxicity |
|       |               |                  | Increases acetylcholine content |
|       |               |                  | Neurite outgrowth and dendritic development |
| 6.    | Guggulu       | Phenols, ferulic acids, and other nonphenolic aromatic acids | Lowers cholesterol (a risk factor for AD) |
|       |               |                  | Regulates synaptic functions and neuronal plasticity |
|       |               |                  | Anti-oxidant effects |
|       |               |                  | Anti-AChE activities |
| 7.    | Ginkgo        | Flavonoid glycosides and terpenoids | Anti-apoptotic effects |
|       |               |                  | Anti-oxidant effects |
|       |               |                  | Anti-inflammatory effects |
|       |               |                  | Protection against Aβ aggregation |
| 8.    | Cinnamon      | Cinnamaldehyde | Inhibits tau aggregation and filament formation |
|       |               |                  | Counters Aβ aggregation |
|       |               |                  | Inhibits AChE activity |
|       |               |                  | Promotes learning and memory |
|       |               |                  | Reduces oxidative stress /nitrative stress in neuronal damage and apoptosis pathways |
|       |               |                  | Anti-inflammatory effects |
|       |               |                  | Immunomodulatory functions |
| 9.    | Ginseng       | Ginsenosides | Improve thinking and working memory |
|       |               |                  | Anti-inflammatory effects |
|       |               |                  | Enhancement of CNS cholinergic function |
|       |               |                  | Anti-apoptotic effects |
| 10.   | Cannabis      | Cannabidiol | Inhibits neuro-inflammation caused by Aβ aggregation |
|       |               |                  | Prevents tau hyperphosphorylation |
|       |               |                  | Enhances memory and learning |
|       |               |                  | Antioxidant effects |

AChE, acetylcholinesterase, AD, Alzheimer’s disease, Aβ, amyloid-β.
NATURAL DIETARY INTAKES

An insightful review article by Islam et al. (2017) sheds light on the importance and use of natural dietary products, like fruits (berries: blueberries, mulberries, and strawberries, apple, fig, mangosteen, papaya, dates, grapes, pomegranate, walnut, etc.), vegetables (broccoli, etc.), spices (cinnamon, black pepper, saffron, turmeric, garlic, ginger, etc.), drinks (tea, coffee, wine, fruit juice, etc.), marine products, and Mediterranean diet, in showing positive effects for AD prevention and treatment. These, thus, have the potential for being developed into therapeutic anti-AD drugs [112].

A recent study by Jabir et al. (2018) shows that polyphenols have a high therapeutic value and are present in plants. Quercetin derived from fruits and vegetables, such as onions, apples, berries, peanuts, soybeans, potatoes, etc.; resveratrol from grapes’ skin and seeds; curcumin from turmeric; cinnamic acid and its derivatives from cinnamon, citrus fruits, tea, cocoa, etc.; caffeine from Coffea arabica and caffeic acid abundantly found in all plants and dietary products, are some of the critical polyphenolic compounds that have been discussed. They inhibit cholinesterase activity, thus, qualifying as potential drugs for AD treatment. However, their exact mechanism of action has not been elucidated [113].

N-acetylcysteine (NAC), abundantly present in onions, is a glutathione (GSH) precursor which is an antioxidant [114]. It is included in the World Health Organization’s List of 40 Essential Medicines, being a well-established drug since the 1960s [115]. GSH levels are depleted in the hippocampal regions in AD, implying that NAC supplementation can be beneficial for cognitive enhancement [116]. A study by Moreira et al. provides evidence that NAC is efficient in enhancing the mitochondrial related oxidative stress in case of AD. It also showed that the combination of lipoic acid and NAC was more potent to use [117].

VITAMINS

Lower levels of vitamin B are often associated with decreasing cognitive ability, commonly due to the increased level of homocysteine [118]. Vitamin B6, B9 (folate), and B12 (cyanocobalamin) are involved in homocysteine metabolism, which can thus be boosted with the help of vitamin B supplementation, resulting in reduced risk of dementia [119].

Vitamin A and C have antioxidant activity, thus their use in enhancing cognition and preventing dementia. Vitamin A (retinol) is essential for memory, learning, and cognition. Its levels in the brain decline with age and are very low in AD patients [120]. Performed retinoids or provitamin carotenoids provide vitamin A, with β-carotene most commonly found in food. In Physicians’ Health Study II (PHSII), a randomized trial of β-carotene supplementation, it was found that long-term use conferred cognitive benefits [121]. Retinoic acid was also reported to protect neurons of the hippocampus by preventing Aβ-induced cell death [122].

A study demonstrated that low vitamin D dietary intake was associated with the poor cognitive performance [123]. Similar results were obtained from another study from the Third National Health and Nutrition Examination Survey (NHANES III).

Vitamin E is a potent antioxidant and anti-inflammatory agent. It also has neuroprotective roles. Lower levels of vitamin E have been reported in AD patients [124,125]. It has shown positive results on cognition. However, further research is required to support the use of vitamin E as a therapeutic agent for AD [126].

Medical food cocktail

According to a study by Parachikova et al., administration of a cocktail that comprised of curcumin, piperine, epigallocatechin gallate, α-lipoic acid, N-acetylcysteine, vitamin B and C, and folate for six months in transgenic mice model of AD resulted in improvement in memory and learning. It also helped in reducing the soluble Aβ concentrations, including Aβ oligomers [127]. Thus, combinations of different medicinal compounds must be extensively studied to derive different formulations that show greater efficacy in their preventive and therapeutic anti-AD usage.

STRESS, MEDITATION, AND AD

Stress, an effect of a threat to homeostasis, is a situation wherein individuals encounter aversive stimuli leading to a negative physiological change [128]. Stress and cortisone (a hormone released by the adrenal gland in response to stress) can activate glucocorticoid receptors, leading to a reduction of hippocampal plasticity. It affects memory (especially spatial memory) and learning, potentially leading to cognitive deterioration and age-linked neurodegener-
ative diseases [129,130]. Excess cortisol production also leads to a decreased volume of right hippocampi and orbitofrontal cortex [131]. It showed that stress diminishes telomerase levels, thus affecting the telomere length and the genetic health of an individual. The accelerated shortening of telomeres is associated with faster aging, inflammation, and AD [132,133]. Managing stress allows alleviating the progression and implications of AD since stress is considered to be a factor that accelerates AD pathology [134,135].

A review by Jesse Russell-Williams et al. analyzed ten different studies, comprising of six studies on mindfulness (mindfulness-based stress reduction, MBSR), three studies on Kirtan Kriya (KK) meditation, and one study on mindfulness-based Alzheimer’s stimulation (MBAS) [136]. The analysis highlights that the investigation by Quintana-Hernandez et al., spanning over two years, shows that mindfulness can be used as a non-pharmacological method to delay cognitive deterioration in case of mild to moderate AD patients, a study based on MBSR and KK [137]. Newberg et al. reported that practicing KK for eight weeks in case of subjective memory loss due to AD or mild cognitive impairment resulted in a significant increase in cerebral blood flow (CBF) within the frontal lobe and right superior parietal lobe [138]. A study by Paller et al. also showed that mindfulness augments attention as assessed by P3-related activity. The pre and post-analysis following eight weeks of MBSR also showed benefits like better subjective sleep quality, improved ratings of quality-of-life, and fewer depressive symptoms [139]. Studies also showed that eight weeks of KK or mindfulness sessions helped in alleviating worry [135] and soaring positive mood and energy [140]. A majority of patients found the experience to have positive impacts since the sessions were relaxing, calming, peaceful, and uplifting [141]. Thus, mindfulness can act as an efficient disease management method, and different kinds of meditation (KK, MBAS, and MBSR) can work as suitable complementary treatments.

Synaptic changes contribute to AD pathogenesis, affecting cognition. Practicing KK has shown to stabilize brain synapses by increasing neurotransmitter levels, including acetylcholine, norepinephrine, glutamate, and possibly GABA [142–144]. KK also activates the posterior cingulate gyrus (PCG) [145] which is a metabolically active region and is vital for memory and emotional functions. Reduced cerebral blood flow and hypometabolism in PCG are considered to be early signs of AD [146]. Thus, regular activation of PCG by KK can significantly contribute to decreasing AD risks [147]. A study analyzed the effects of KK on caregivers and reported that practicing KK for eight weeks helps in lowering depressive symptoms, boosting mental health, memory, and well-being. It improved the telomerase activity as well, suggesting an alleviation of stress-induced cellular aging [148]. Practicing KK also enhances sleep, poor sleep being a risk factor in the case of AD [149]. KK is thus proved to be an effective, safe, and free of side-effects. It is a self-directed program that is easy to learn and is affordable. It can be used to complement pharmacological treatments for increased preventive or therapeutic results [147].

A study by Luders et al. highlights that the brain age of people who have regularly been meditating for an extended period is found to be is 7.5 years lesser than that of the non-practitioners. The brain age was calculated using a machine learning algorithm, and scores obtained in years as BrainAGE index. Not just were the brains of practitioners of meditation found to be younger, but with every passing year, meditators’ age reduced by one month and 22 days than their chronical age. Thus, there was a positive impact of meditation on the preservation of the brain and its activity. Therefore, by reducing the age-related atrophy, meditation slows the rate of brain aging [150].

EXERCISE AND AD

Higher levels of daily physical activity and exercise, complemented by bright light and proper nutrients [151], aid in lowering the chances of AD development [152]. Regular walking shows improvement in cognition [153]. In people aged 60 years or more, regular aerobic exercises enhance the production of gray and white matters in the cortical regions [154]. Physical activities, such as treadmill, ergo cycle, stair-climbing, etc., done for 40 min over 12 weeks consecutively, contribute to neuroprotective mechanisms of reduction of Aβ plaques, and increase blood flow to the cerebral region that improves neurogenesis and synaptogenesis, that will enhance memory and cognitive functions. The increased blood flow results in developing vascular reserve and maintenance of neuronal plasticity due to the activation of NO/endothelial NO synthase, thus lowered cerebrovascular and endothelial dysfunction pathophysiology is seen [155]. Exercise upregulates the
production of neurotrophins which are responsible for neurogenesis, improved memory, and brain plasticity [156].

Regular physical exercising helps in reducing the rate of production of ROS, which is associated with the onset and progression of AD. Exercising helps escalate the activity and the level of antioxidant enzymes in different regions of the brain. Thus, reducing oxidative stress [157]. Regular exercising causes a reduction in the levels of lipid peroxidation and protein oxidation. It can also limit ROS production by decreasing the ROS generating source itself or attenuating ROS generating capacity [158]. Therefore, it acts as a preventive tool to combat AD. Physical activity not only thwarts the effects of oxidative stress but also helps in lowering cholesterol and insulin resistance, subsequently leading to increased vascularization and improved energy metabolism, such as glucose metabolism [159].

A study by Nagarah et al. has shown that BDNF is critical for the upkeep of adult cortical neurons of the entorhinal cortex, whose early dysfunction furthers the initial short-term memory loss in AD. Thus, administration of BDNF helps in reversal of synapse deterioration, normalization of aberrant gene expression as well as the restoration of memory and learning [160]. Moderate to high-intensity physical exercise intensifies BDNF production, thus, bringing about its positive impacts [161].

In older healthy subjects and AD patients following one year of moderately intense aerobic exercise, i.e., 40-min session, three days per week, showed an increase of more than 2% in hippocampal volume and plasma concentration of BDNF [162]. The environmental conditions also play a crucial role in BDNF enhancement as mice trained in enriched environment showed more significant environment-related cognitive improvement in BDNF, hippocampal neurotrophin, and activation of hippocampal neurogenesis. By enriching environmental conditions, BDNF production can thus be enhanced [157]. Decrease of neurofibrillary degeneration and neuroinflammation attributed to physical training, along with prevention of loss of choline acetyltransferase expression [163,164].

Neurotrophins are proteins that mediate neuronal survival and differentiation during development, maintain neuronal viability in adults by protecting and restoring neurons in case of injury or aging. They also function as activity-dependent modulators of synaptic plasticity [165] in which BDNF is known to be an essential mediator in memory centers of the brain [166]. Neurotrophins also have the potential to regulate genes coding for structural proteins, enzymes, or neurotransmitters, thus, modifying neuronal morphology and function. With the right standardization and universal protocols, this can be used to prescribe appropriate levels of physical exercises for brain health and to alleviate AD conditions [167].

As per a recent finding, the beneficial effects of exercising on AD models are mediated by irisin, a hormone initially discovered as an exercise-induced myokine that leads to thermogenesis and adipocyte browning, and is cleaved from a transmembrane precursor protein, fibronectin type III domain-containing protein 5 (FNDC5). Under the control of peroxisome proliferator-activated receptor-γ coactivator 1α, FNDC5 is expressed in muscle [168]. FNDC5/irisin stimulates the expression of BDNF in the hippocampus. In the case of AD, FNDC5/irisin levels are lowered in the hippocampi and cerebrospinal fluid, thus leading to impairment of cognition and novel object recognition memory. Regular physical exercise boosts the molecular levels of FNDC5/irisin, which thus mediates protection and repair of synapse function and memory impairment, and prevents cognitive decline in AD [169].

**ACUPUNCTURE**

Acupuncture is a traditional Chinese practice that is said to be more than 3,000 years old. It is gaining global recognition as a complementary medicine system for a variety of conditions [170]. It involves the application of heat or pressure or insertion of sharp, thin needles into the specific points on the body to stimulate nerve receptors via the connective tissue surrounding the site of application. It is aided by mechanical, electrical, or other physical manipulations [171]. Acupuncture with deeper needling is shown to induce stronger, wider-ranging *de qi* sensations and enhance nodal centrality, chiefly in the abnormal brain regions in case of mild cognitive impairment. It was reported by a small-scale functional magnetic resonance imaging study that examined the effect of *de qi* sensations induced by different needling depths on the reorganizations of whole-brain networks [172].

Some studies support the benefits of acupuncture in case of AD [173]. Eighty-seven patients with mild-to-moderate AD were involved in a clinical
A. Sharma and Y. Kumar / Nature’s Derivative(s) as Alternative Anti-AD Treatments

trial in which acupuncture treatment, when used as a monotherapy for 12 weeks, resulted in substantial lowering in ADAS-cog scores from baseline compared with the use of donepezil. The study emphasized that acupuncture is safe and effective in improving cognitive function [174]. Ding et al. showed that manual acupuncture could significantly improve spatial learning, relearning, and memory abilities in SAMP8 mice models of AD. It could be due to the increase in CBF in prefrontal lobe and hippocampus due to the acupuncture treatment since a reduction in CBF considered a sensitive biomarker to early perfusion deficiencies in AD [175].

RHEUMATOID ARTHRITIS AND AD

Rheumatoid arthritis (RA), an autoimmune disease, is marked by synovial inflammation, cartilage and bone destruction, and autoantibody production, causing progressive disability. RA has also been linked to cardiovascular disease, diabetes mellitus, and depression. RA also causes inflammation of the heart, lungs, and blood vessels [176]. Thus, inflammation is a common implication observed in case of both RA and AD. Common inflammatory biomarkers found in the two provide evidence for the same. These include IL-6 [177,178], pentraxin 3 [179,180], resistin [179,181], etc. There is epidemiological evidence for reduced AD incidence in the case of RA due to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) [182].

A study by Judge et al., based on observational studies and experimental data, highlights the inverse relationship between the manifestation of RA and AD. It shows that the use of classical disease-modifying antirheumatic drugs (cDMARDs) decreased AD risk, with methotrexate (MTX) being the most effective cDMARD in the study. Thus, the protective effect of cDMARD was independent of that of NSAIDs. This study brings forth the potential therapeutic use of cDMARDs in treatment of AD [183]. MTX shows limited penetrance potential of the BBB. However, even moderate penetrance shows therapeutic effects. At higher doses, it is used to treat brain tumors [184]. According to a study, administration of GM-CSF, which gets upregulated in RA, helped in reducing Aβ load and alleviating cognitive impairments in mice models of AD. The study highlighted the use of the recombinant human form of GM-CSF (Leukine®), approved by the FDA, as a therapeutic agent for AD [185].

DIABETES AND AD

Insulin signaling is damaged in the brain in the case of AD [186]. A review article by Kamal et al. highlights the similarities between AD and type 2 diabetes mellitus (T2DM) including impaired brain insulin signaling, abnormal brain glucose metabolism, amyloidogenesis, mitochondrial dysfunction, inflammation, and oxidative stress. It emphasizes that the interrelation between the two is complex and that with T2DM, AD incidences also increase. Thus, the mechanisms and factors that are common can be potential therapeutic targets [187].

The neuroprotective effect of an antidiabetic drug, triple receptor agonist (TA), that can activate glucagon-like peptide-1, glucose-dependent insulinothropic polypeptide, and glucagon receptors, was tested in the APPSWE/PS1E9 mouse model of AD. TA treatment leads to memory and learning enhancement and reduction of amyloid plaques in the brain. It did not just ease the chronic inflammation by activating microglia and astrocytes but also reduced oxidative stress in hippocampus and cortex. TA also helped in reducing the levels of the mitochondrial pro-apoptotic signaling molecule BAX, increasing the anti-apoptotic signaling molecule Bcl-2, and enhancing the levels of BDNF, growth factor that protects synaptic function. The synaptic loss got prevented, indicated by a rise in levels of synaptophysin. It also enhanced the neurogenesis in the dentate gyrus. Thus, TA is a potential drug for AD [188].

CONCLUSION

As the global population continues to increase, the number of people affected by age-related disorders such as AD is going to increase manifold. It is predicted among the aging population, that the number of AD cases will escalate to 135 million by 2050. Thus, alternative preventive and therapeutic strategies are attracting mounting attention for advanced research and development of appropriate medicine systems. It is attributed to their efficacy and safe usage as they are shown to have little or no side effects and potential to provide overall wellbeing.

AD is not just crippling for the health of the patient but also imposes an economic burden on the patients and caregivers as it demands long-term medication, healthcare, and caregiving services, thus, necessitating the need to promptly formulate and adapt economically viable long-term medication and
assistance systems to address the concerning rise of AD incidences in the coming future.

Ayurveda drugs including turmeric, Brahmi, etc., natural dietary products, vitamins, meditation and management of stress, regular exercising, and traditional Chinese practices are significant in contributing toward the development of such alternative strategies. The anti-AD treatment systems discussed to provide an economical alternative to strive to combat the disease, derived from nature or naturally existing resources. Besides, various drugs in use for RA as well as diabetes also have therapeutic potential for anti-AD treatment. To efficiently establish the effectiveness of the alternative therapeutic and preventive strategies suggested, research studies with more extensive sampling size and appropriate control groups are required.

It would be correct to conclude that the alternative strategies discussed have proven to be efficient in preventing, treating, curing, or managing AD. They have also proven to be useful for the wellbeing of the caregivers. The drugs and treatment options currently available do not fully cure or reverse the effects of the disease. These strategies can thus be used in combinations to complement the mainstream AD treatments presently being used for better management of the disease condition and increased cognition and memory of the patients.

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

[1] Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging 19, 173-189.
[2] World Health Organization (2012) Dementia: A public health priority, https://www.who.int/mental_health/publications/dementia_report_2012/en/.
[3] Guerreiro R, Bras J (2015) The age factor in Alzheimer’s disease. Genome Med 7, 1-3.
[4] Reddy VS, Bukke S, Dutt N, Rana P, Pandey AK (2017) A systematic review and meta-analysis of the circulatory, erythrocytellar and CSF selenium levels in Alzheimer’s disease: A meta meta-analysis (AMMA study-I). J Trace Elem Med Biol 42, 68-75.
[5] Evans PH, Klinowsky J, Yano E, Urano N (1989) Alzheimer’s disease: A pathogenic role for aluminosilicate-induced phagocytic free radicals. Free Radic Res 6, 317-321.
[6] Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P, Xu H (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc Natl Acad Sci U S A 96, 742-747.
[7] Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101, 1371-1378.
[8] Ballatore C, Lee VM-Y, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8, 663-672.
[9] Li X, Kumar Y, Zempel H, Mandelkow E-M, Bierat J, Mandelkow E (2011) Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 30, 4825-4837.
[10] Katsumoto A, Takeuchi H, Takahashi K, Tanaka F (2018) Microglia in Alzheimer’s disease: Risk factors and inflammation. Front Neurol 9, 978.
[11] Gupta A, Iadecola C (2015) Impaired Aβ clearance: A potential link between atherosclerosis and Alzheimer’s disease. Front Aging Neurosci 7, 115.
[12] Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G (2015) Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease. Front Cell Neurosci 9, 65.
[13] National Institute on Aging. What Happens to the Brain in Alzheimer’s Disease? https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease
[14] Newberg AB, Serruya M, Wintering N, Moss AS, Reibel D, Monti DA (2014) Meditation and neurodegenerative diseases. Ann N Y Acad Sci 1307, 112-123.
[15] Mesulam MM (1983) The functional anatomy and hemispheric specialization for directed attention. The role of the parietal lobe and its connectivity. Trends Neurosci 6, 384-387.
[16] Saxe R, Kanwisher N (2003) People thinking about thinking people. The role of the temporo-parietal junction in “theory of mind”. Neuroimage 19, 1835-1842.
[17] Wagner AD, Shannon BJ, Kahn I, Buckner RL (2005) Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci 9, 445-453.
[18] Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29, 417-426.
[19] Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 6, 37.
[20] National Institute on Aging. How Is Alzheimer’s Disease Treated? https://www.nia.nih.gov/health/how-alzheimers-disease-treated
[21] Alzheimer’s Disease International. Dementia statistics, https://www.alz.co.uk/research/statistics
[22] Alzheimer’s Association (2019) 2019 Alzheimer’s Disease Facts And Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures-2019-r.pdf
[23] Meena DK, Upadhyay D, Singh R, Dhibedh BK (2015) A critical review of fundamental principles of Ayurveda. Int Ayurvedic Med J 3, 2075-2083.
[24] Farooqui AA, Farooqui T, Madan A, Ong JHI, Ong WY (2018) Ayurvedic medicine for the treatment of dementia: mechanistic aspects. Evid Based Complement Alternat Med 2018, 2481076.
[25] Bhattacharya SK, Ghosal S (1998) Anxiolytic activity of a standardized extract of Bacopa monniera: An experimental study. Phytomedicine 5, 77-82.
[26] Roomeys S, Booth D, Bulzomi S, Phipps A,Micallef C, Smoker J (2002) Chronic effects of Brahmi (Bacopa
[27] Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S (2000) Antioxidant activity of Bacopa monnieri in rat frontal cortex, striatum and hippocampus. *Phytother Res* **14**, 174-9.

[28] Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS (2017) Neurocognitive effect of nootropick drug Brahmi (Bacopa monnieri) in Alzheimer’s disease. *Ann Neurosci* **24**, 111-122.

[29] Le XT, Pham HTN, Do PT, Fujiwara H, Tanaka K, Li F, Van Nguyen T, Nguyen KM, Matsumoto K (2013) Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: Possible involvement of glutamatergic and cholinergic systems. *Neurochem Res* **38**, 2201-2215.

[30] Ubundit N, Wattanathom J, Mucimapura S, Inkgkanan K (2010) Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. *J Ethnopharmacol* **127**, 26-31.

[31] Mathew M, Subramanian S (2012) Evaluation of the anti-amyloidogenic potential of nootropic herbal extracts in vitro. *Int J Pharm Sci Res* **31**, 4276-4280.

[32] Holcomb LA, Dhanasekaran M, Hitt AR, Young KA, Pasuriwong O, Piyawatkul N, Yimtae K, Sripanidkulchai B, Singkhoraard J (2008) Positive modulation of cognitive function and cholinergic systems. *Neuropsychopharmacology* **33**, 2201-1105.

[33] Patil D, Gautam M, Mishra S, Karupothula S, Gairola S, Jadhav S, Pawar S, Patwardhan B (2013) Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. *J Pharm Biomed Anal* **80**, 203-212.

[34] Sandhir R, Sood A (2017) Neuroprotective potential of Withania somnifera (ashwagandha) in neurological conditions. In *Science of Ashwagandha: Preventive and Therapeutic Potentials*. Springer International Publishing, pp. 373-387.

[35] Song Y, Li R, Cui J, Hannink M, Gu Z, Fritsche KL, Lubahn DB, Simony A (2016) Withania somnifera and its withanolides attenuate oxidative and inflammatory responses and up-regulate antioxidant responses in BV-2 microglial cells. *Neuromolecular Med* **18**, 241-252.

[36] Kuboyama T, Tohda C, Komatsu K (2014) Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. *Biol Pharm Bull* **37**, 892-897.

[37] Goel A, Kunnunakkara AB, Aggarwal BB (2008) Curcumin as “Curecumin”: From kitchen to clinic. *Biochem Pharmacol* **75**, 787-809.

[38] Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem* **280**, 5892-5901.

[39] Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, Zhou F, Jin LW, Hua DH (2009) Inhibition of Alzheimer’s amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. *J Neurochem* **108**, 1097-1108.

[40] Wang Y, Yin H, Wang L, Shuboy A, Lou J, Han B, Zhang X, Li J (2013) Curcumin as a potential treatment for Alzheimer’s disease: A study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. *Am J Chin Med* **41**, 59-70.

[41] Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. *Biochem Pharmacol* **85**, 705-717.

[42] Ng T-P, Chiam P-C, Lee T, Chua H-C, Lim L, Kua E-H (2006) Curry consumption and cognitive function in the elderly. *Am J Epidemiol* **164**, 898-906.

[43] Mishra S, Palanivelu K (2008) The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. *Ann Indian Acad Neurol* **11**, 13-19.

[44] Tang M, Taghibiglou C (2017) The Mechanisms of action of curcumin in Alzheimer’s disease. *J Alzheimers Dis* **58**, 1003-1016.

[45] Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* **64**, 353-356.

[46] Malik J, Karan M, Vissht K (2011) Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. *Pharm Biol* **49**, 1234-1242.
Bridi R, Praveen K, Kamlesh D (2014) Indian traditional memory enhancing herbs and their medicinal benefits. *Indian J Res Pharm Biotechnol* 2, 1030.

Kizhakke PA, Olakkaran S, Antony A, Tilagul KS, Hunasahanally PG (2019) Convulvulus pluricaulis (Shankhapushpi) ameliorates human microtuble-associated protein tau (hMAPpr) induced neurotoxicity in Alzheimer’s disease Drosophila model. *J Chem Neuroanat* 95, 115-122.

Rai KS, Murthy KD, Karanth KS, Nalini K, Rao MS, Srinivasan KK (2002) Chitoria ternatea root extract enhances acetylcholine content in rat hippocampus. *Fitoterapia* 73, 685-689.

Sarup P, Bala S, Kamboj S (2015) Pharmacology and phytochemistry of oleo-gum resin of Commiphora wightii (Guggulu). *Scientifica (Cairo)* 2015, 1-14.

Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Cini C, Butterfield DA (2006) In vivo protective effects of ferulic acid ethyl ester against amyloid-b peptide 1-42 induced oxidative stress. *J Neurosci Res* 84, 418-426.

Butterfield DA, Boyd-Kimball D (2018) Oxidative stress, amyloid-β peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer’s disease. *J Alzheimers Dis* 62, 1345-1367.

Nohr LA, Rasmussen LB, Straand J (2009) Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. *Complement Ther Med* 17, 16-22.

Morley JE, Banks WA (2010) Lipids and cognition. *J Alzheimers Dis* 20, 737-747.

Chen Z, Huang C, Ding W (2016) Z-guggulsterone improves the scopolamine-induced memory impairments through enhancement of the BDNF signal in C57BL/6J mice. *Neurochem Res* 41, 3322-3332.

Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C (2007) Gugulipid, an extract of Commiphora whightii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. *Pharmacol Biochem Behav* 86, 797-805.

Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J (2009) Protective effects of Ginkgo biloba leaf extract (EGB761) and its constituents quercetin and ginkgolide B against amyloid-β peptide-induced toxicity in SH-SY5Y cells. *Chem Biol Interact* 181, 115-123.

Macleanen KM, Darlington CL, Smith PF (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. *Prog Neurobiol* 67, 233-257.

Wei T, Ni Y, Hou J, Chen C, Zhao B, Xin W (2000) Hydrogen peroxide-induced oxidative damage and apoptosis in cerebellar granule cells: Protection by ginkgo biloba extract. *Pharmacol Res* 41, 427-433.

Ahlemeyer B, Kriegstein J (2003) Neuroprotective effects of Ginkgo biloba extract. *Cell Mol Life Sci* 60, 1779-1792.

Bridi R, Crossetti FP, Steffen VM, Henriques AT (2001) The antioxidant activity of standardized extract of Ginkgo biloba (EGb761) in rats. *Phytother Res* 15, 449-451.

Gargouri B, Carstensen J, Bhata H, Huel M, Dietz GPH, Fiebich BL (2018) Anti-neuroinflammatory effects of Ginkgo biloba extract EGB761 in LPS-activated primary microglial cells. *Phymomedicine* 44, 45-55.

Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, M¨unch G (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. *Eur J Neurosci* 14, 1961-1967.

Bonavida B, Mencia-Huerta JM (1994) Platelet-activating factor and the cytokine network in inflammatory processes. *Clin Rev Allergy* 12, 381-395.

Smith JV, Luo Y (2004) Studies on molecular mechanisms of Ginkgo biloba extract. *Appl Microbiol Biotechnol* 64, 465-472.

Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J (2009) Dosage effects of EGB761 on hydrogen peroxide-induced cell death in SH-SY5Y cells. *Chem Biol Interact* 180, 389-397.

Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R (2000) The Ginkgo biloba extract (EG61) protects hippocampal neurons against cell death induced by beta-amyloid. *Eur J Neurosci* 12, 1882-1890.

Smith JV, Luo Y (2003) Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGB 761. *J Alzheimers Dis* 5, 287-300.

Shi C, Liu J, Wu F, Yew DT (2010) Ginkgo biloba extract in Alzheimer’s disease: From action mechanisms to medical practice. *Int J Mol Sci* 11, 107-123.

Pierre S, Jamme I, Droy-Lefaix MT, Nouvelot A, Maixent JM (1999) Ginkgo biloba extract (EGB 761) protects Na,K-ATPase activity during cerebral ischemia in mice. *Neuroreport* 10, 47-51.

Zheng SX, Zhou LJ, Chen ZL, Yin ML, Zhu XZ (2000) Bilobalide promotes expression of glial cell line-derived neurotrophic factor and vascular endothelial growth factor in rat astrocytes. *Acta Pharmacol Sin* 21, 151-155.

Ihl R, Tribanek M, Bachinskaya N, GOTADAY Study Group (2012) Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGB 761® in Alzheimer’s disease and vascular dementia: results from a randomised controlled trial. *Pharmacopsychiatry* 45, 41-46.

Savaskan E, Mueller H, Hoerr R, von Gunten A, Gaubier S (2018) Treatment effects of Ginkgo biloba extract EGB 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. *Int Psychogeriatrics* 30, 285-293.

Ren C, Ji Y-Q, Liu H, Wang Z, Wang J-H, Zhang C-Y, Guan L-N, Yin P-Y (2019) Effects of Ginkgo biloba extract EGB761 on neural differentiation of stem cells offer new hope for neurological disease treatment. *Neural Regen Res* 14, 1152-1157.

Kennedy DO, Haskell CF, Maurl PL, Scholey AB (2007) Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. *Hum Psychopharmacol* 22, 199-210.

Gunawardena D, Karunaweera N, Lee S, van Der Kooy F, Harman DG, Raju R, Bennett L, Gyengesi E, Sucher NJ, Munch G (2015) Anti-inflammatory activity of cinnamon (C. zeylanicum and C. cassia) extracts - identification of E-cinnamaldehyde and o-methoxy cinnamaldehyde as the most potent bioactive compounds. *Food Funct* 6, 910-919.

Chen Y-F, Wang Y-W, Huang W-S, Lee M-M, Wood WG, Leung Y-M, Tsai H-Y (2016) Trans-cinnamaldehyde, an essential oil in cinnamon powder, ameliorates cerebro-vascular ischemia-induced brain injury via inhibition of
neuroinflammation through attenuation of iNOS, COX-2 expression and NFκB signaling pathway. *Neuro molecular Med* **18**, 322-333.

[89] George RC, Lew J, Graves DJ (2013) Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer’s disease pathogenesis. *J Alzheimers Dis* **36**, 21-40.

[90] Wang J, Ferruzzi MG, Ho L, Blount J, Janle EM, Gong B, George RC, Lew J, Graves DJ (2013) Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer’s disease pathogenesis. *J Alzheimers Dis* **36**, 21-40.

[91] Zhang L, Zhang Z, Fu Y, Yang P, Qin Z, Chen Y, Kang YJ, Seo D-G, Park S-Y (2016) Phenylpropanoids in Panax notoginseng treatment for Alzheimer’s disease. *Psychopharmacology (Berl)* **152**, 353-361.

[92] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[93] Grotenhermen F (2003) Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet **42**, 327-360.

[94] Wesnes KA, Ward T, McGinty A, Petrini O (2000) The pharmacological properties of monoterpenes: a review. *Pharmacol Biochem Behav **75**, 701-719.

[95] Grotenhermen F, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[96] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[97] Grotenhermen F, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[98] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[99] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[100] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.

[101] Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Stelaro L (2007) Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. *Br J Pharmacol* **151**, 1272-1279.
cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. *Alzheimers Dis* **12**, 195-206.

[118] Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. *Am J Clin Nutr* **82**, 627-635.

[119] Ford AH, Flicker L, Alfonso H, Thomas J, Clarrette R, Martins R, Almeida OP (2010) Vitamins B(12), B(6), and folic acid for cognition in older men. *Neurology* **75**, 1540-1547.

[120] Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM (2007) A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians’ Health Study II. *Arch Intern Med* **167**, 2184-2190.

[121] Sahin M, Kara¨uz¨um SB, Perry G, Smith MA, Alicig¨uzel Y, Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Casati M, Boccardi V, Ferri E, Bertagnoli L, Bastiani P, de Kloet ER, Oitzl MS, Jo ¨els M (1999) Stress and cognition: Are corticosteroids good or bad guys? *Front Psychol* **13**, 419-426.

[122] Llewellyn DJ, Lang IA, Langa KM, Melzer D (2011) Vitamin D and cognitive impairment in the elderly U.S. population. *J Gerontol A Biol Sci Med Sci* **66A**, 59-65.

[123] Casati M, Boccardi V, Ferri E, Bertagnoli L, Bastiani P, Ciccone S, Mansi M, Scamosci M, Rossi PD, Meccoci P, Arosio B (2019) Vitamin E and Alzheimer’s disease: the mediating role of cellular aging. *Aging Clin Exp Res*, doi: 10.1007/s40520-019-01209-3.

[124] Russell RM, Suter PM (2015) Vitamin and trace mineral deficiency and excess. In *Harrison’s Principles of Internal Medicine, 19th edition*, Kasper D, Fauci A, Hauser S et al., eds. McGraw-Hill, New York.

[125] Lloret A, Esteve D, Monllor P, Cervera-Ferri A, Lloret A (2019) The effectiveness of vitamin E treatment in Alzheimer’s disease. *Int J Mol Sci* **20**, E879.

[126] Parachikova A, Green KN, Hendrix C, Laferla FM (2010) Formulation of a medical food cocktail for Alzheimer’s disease: Beneficial effects on cognition and neuropathology in a mouse model of the disease. *PLoS One* **5**, e14015.

[127] Schneiderman N, Ironson G, Siegel SD (2005) Stress and health: psychological, behavioral, and biological determinants. *Annu Rev Clin Psychol* **1**, 607-628.

[128] de Kloet ER, Oitzl MS, Joels M (1999) Stress and cognition: Are corticosteroids good or bad guys? *Trends Neurosci* **22**, 422-426.

[129] Kim JJ, Diamond DM (2002) The stressed hippocampus, synaptic plasticity and lost memories. *Nat Rev Neurosci* **3**, 453-462.

[130] Gianaros PJ, Jennings JR, Sheu LK, Greer PJ, Kuller LH, Matthews KA (2007) Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus. *Neuroimage* **35**, 795-803.

[131] Epel ES, Lin J, Dhabhar FS, Wolkowitz OM, Puterman E, Karan L, Blackburn EH (2010) Dynamics of telomerase activity in response to acute psychological stress. *Brain Behav Immun* **24**, 531-539.

[132] Lukens JN, Van Deerlin V, Clark CM, Xie SX, Johnson FB (2009) Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer’s disease. *Alzheimers Dement* **5**, 463-469.

[133] Katz MJ, Derby CA, Wang C, Sliwinski MJ, Ezzati A, Zimmerman ME, Zwering JL, Lipton RB (2016) Influence of perceived stress on incident amnestic mild cognitive impairment: results from the Einstein Aging Study. *Alzheimer Dis Assoc Disord* **30**, 93-98.

[134] Khalsa DS (2015) Stress, meditation, and Alzheimer’s disease. *Aging Clin Exp Res* **29**, 791-804.

[135] Looije E, Hickman S, Hershey T, Wendleton L, Ly K, Dixon D, Dori P, Wetherell JL (2014) Mindfulness-based stress reduction for older adults with worry symptoms and co-occurring cognitive dysfunction. *Int J Geriatr Psychiatry* **29**, 991-1000.

[136] Russell-Williams J, Jaroudi W, Perich T, Hoscheidt S, El Haj M, Moustafa AA (2018) Mindfulness and meditation: treating cognitive impairment and reducing stress in dementia. *Rev Neurosci* **29**, 791-804.

[137] Quintana-Hernández DJ, Miró-Barrachina MT, Ibáñez-Fernández JJ, Pino AS-D, Quintana-Montesdeoca MP, Rodríguez-de Vera B, Morales-Casanova D, Pérez-Vieitez MDC, Rodríguez-García J, Bravo-Caraduje N (2016) Mindfulness in the maintenance of cognitive capacities in Alzheimer’s disease: A randomized clinical trial. *J Alzheimers Dis* **50**, 217-232.

[138] Newberg AB, Winttering N, Khalsa DS, Roggenkamp H, Waldman MR (2010) Meditation effects on cognitive function and cerebral blood flow in subjects with memory loss: A preliminary study. *J Alzheimers Dis* **20**, 517-526.

[139] Paller KA, Creery JD, Florczak SM, Weintraub S, Mesulam MM, Reber PJ, Kiragu J, Rooks J, Safron A, Morhardt D, O’Hara M, Gigler KL, Molony JM, Maslar M (2015) Benefits of mindfulness training for patients with progressive cognitive decline and their caregivers. *Am J Alzheimers Dis Other Demen* **30**, 257-267.

[140] Innes KE, Selfe TK, Khalsa DS, Kandati S (2016) Effects of meditation versus music listening on perceived stress, mood, sleep, and quality of life in adults with early memory loss: A pilot randomized controlled trial. *J Alzheimers Dis* **52**, 1277-1298.

[141] Innes KE, Selfe TK, Khalsa DS, Kandati S (2016) A randomized controlled trial of two simple mind-body programs, Kirtan Kriya meditation and music listening, for adults with subjective cognitive decline: Feasibility and acceptability. *Complement Ther Med* **26**, 98-107.

[142] Nash JD, Newberg A (2013) Toward a unifying taxonomy and definition for meditation. *Front Psychol* **4**, 806.

[143] Newberg AB, Iversen J (2003) The neural basis of the mediating role of cellular aging. *Aging Clin Exp Res*, doi: 10.1007/s40520-019-01209-3.

[144] Streeter CC, Jensen JE, Perlmuter RM, Cabral HJ, Tian H, Terhune DB, Ciraulo DA, Renshaw PF (2007) Yoga Asana sessions increase brain GABA levels: A pilot study. *J Altern Complement Med* **13**, 419-426.

[145] Khalsa DS, Amen D, Hanks C, Money N, Newberg A (2009) Cerebral blood flow changes during chanting meditation. *Nucl Med Commun* **30**, 956-961.

[146] Leech R, Sharp DJ (2014) The role of the posterior cingulate cortex in cognition and disease. *Brain* **137**(Pt 1), 12-32.

[147] Khalsa DS (2015) Stress, meditation, and Alzheimer’s disease prevention: where the evidence stands. *J Alzheimers Dis* **48**, 1-12.

[148] Lavretsky H, Epel ES, Siddharth P, Nazarian N, Cyr NS, Khalsa DS, Lin J, Blackburn E, Irwin MR (2013) A pilot study of yogic meditation for family dementia caregivers with depressive symptoms: effects on mental health, cognition, and telomerase activity. *Int J Geriatr Psychiatry* **28**, 57-65.
Schoels MM, Van Der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murikama MM, Nishimoto N, Smolen JS (2013) Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement. *Ann Rheum Dis* **72**, 583-589.

Chi GC, Fitzpatrick AL, Sharma M, Jenny NS, Lopez OL, DeKosky ST (2017) Inflammatory biomarkers predict domain-specific cognitive decline in older adults. *J Gerontol A Biol Sci Med Sci* **72**, 796-803.

Huang XL, Zhang L, Duan Y, Wang YJ, Wang J (2016) Association of pentraxin 3 with autoimmune diseases: A systematic review and meta-analysis. *Arch Med Res* **47**, 223-231.

Huang Q, Tao S-S, Zhang Y-J, Zhang C, Li L-J, Zhao W, Zhao M-Q, Li P, Pan H-F, Mao C, Ye D-Q (2015) Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. *Clin Rheumatol* **34**, 1713-1720.

McGeer PL, McGeer E, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer disease. *Lancet* **335**, 1037.

Policicchio S, Ahmad AN, Powell JF, Proiisi P (2017) Rheumatoid arthritis and risk for Alzheimer’s disease: A systematic review and meta-analysis and a Mendelian Randomization study. *Sci Rep* **7**, 12861.

Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwell EA (2007) Chemotherapy delivery issues in central nervous system malignancy: A reality check. *J Clin Oncol* **25**, 2295-2305.

Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, Arendash GW, Potter H (2010) GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. *J Alzheimers Dis* **21**, 507-518.

Muloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. *Neurobiol Aging* **31**, 224-243.

Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH (2014) Linking Alzheimer’s disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. *CNS Neurol Disord Drug Targets* **13**, 338-346.

Tai J, Liu W, Li Y, Li L, Hölscher C (2018) Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. *Brain Res* **1678**, 64-74.